Effects of raloxifene on brachial arterial endothelial function, carotid wall thickness, and arterial stiffness in osteoporotic postmenopausal women

International Heart Journal

Volumn 51, Issue 1, 2010, Pages 60-67

  Sumino, Hiroyuki ^a   Ichikawa, Shuichi ^b   Kasama, Shu ^b   Takahashi, Takashi ^c   Sakamoto, Hironosuke ^a   Koizumi, Akira ^b   Kanai, Hiroyoshi ^b   Araki, Yoshihiro ^b   Itoh, Toshio ^b   Iwasaki, Toshiya ^b   Sawada, Yoshie ^b   Saito, Yuichiro ^d   Kumakura, Hisao ^b   Takayama, Yoshiaki ^b   Kanda, Tsugiyasu ^e   Murakami, Masami ^d   Sakamaki, Tetsuo ^d   Kurabayashi, Masahiko ^d  

^a TAKASAKI UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^b Cardiovascular Hospital of Central Japan   (Japan)

^c Tokyo Metropolitan Health and Medical Treatment Corporation   (Japan)

^d GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Arterial stiffness; Carotid wall thickness; Endothelial function; Postmenopausal women; Raloxifene

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIURETIC AGENT; ESTRADIOL; FOLLITROPIN; GLUCOSE; GLYCERYL TRINITRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALOXIFENE; TRIACYLGLYCEROL;

ADULT; AGED; ANKLE; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTERY BLOOD FLOW; ARTERY ENDOTHELIUM; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; BONE DENSITY; BRACHIAL ARTERY; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DYSLIPIDEMIA; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; JAPANESE; LUMBAR SPINE; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PULSE WAVE; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION;

AGED; ATHEROSCLEROSIS; BLOOD GLUCOSE; BLOOD PRESSURE; BONE DENSITY; BRACHIAL ARTERY; CAROTID ARTERIES; ENDOTHELIUM, VASCULAR; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HEART RATE; HUMANS; LIPIDS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS; PULSE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; VASODILATION;

EID: 76749086943     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.51.60     Document Type: Article

References (50)

1. Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at API sites. Science 1997; 277: 1508-10.
2. Bryant HU, Glasebrook AL, Yang NN, Sato M. An estrogen receptor basis for raloxifene action in bone. J Steroid Biochem Mol Biol 1999; 69: 37-44. (Review)
3. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281: 2189-97.
4. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 2002; 287: 847-57.
5. Collins P, Mosca L, Geiger MJ, et al. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors. Circulation 2009; 119: 922-30.
6. Behrendt D, Ganz P. Endothelial function. From vascular biology to clinical applications. Am J Cardiol 2002; 90: 40L-8. (Review)
7. Raitakari OT, Celermajer DS. Flow-mediated dilatation. Br J Clin Pharmacol 2000; 50: 397-404. (Review)
8. Simon A, Gariepy J, Chironi G, Megnien JL, Levenson J. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens 2002; 20: 159-69. (Review)
9. O'Rourke MF, Mancia G. Arterial stiffness. J Hypertens 1999; 17: 1-4. (Review)
10. Saitta A, Altavilla D, Cucinotta D, et al. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilatation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001; 21: 1512-9.
11. Colacurci N, Fornaro F, Cobellis L, et al. Raloxifene slows down the progression of intima-media thickness in postmenopausal women. Menopause 2007; 14: 879-84.
12. da Costa LS, de Oliveira MA, Rubim VS, et al. Effects of hormone replacement therapy or raloxifene on ambulatory blood pressure and arterial stiffness in treated hypertensive postmenopausal women. Am J Cardiol 2004; 94: 1453-6.
13. Tritos NA, Goepfert L, Kissinger KV, et al. Effect of raloxifene on aortic elasticity in healthy postmenopausal women. Am Heart J 2005; 150: 1212.
14. von der Recke P, Hansen MA, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 1999;106:273-8.
15. Mosca L, Manson JE, Sutherland SE, Langer RD, Manolio T, Barrett-Connor E. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group. Circulation 1997; 96: 2468-82.
16. Sumino H, Ichikawa S, Kasama S, et al. Relationship between brachial arterial endothelial function and lumbar spine bone mineral density in postmenopausal women. Circ J 2007; 71: 1555-9.
17. Sanada M, Taguchi A, Higashi Y, et al. Forearm endothelial function and bone mineral loss in postmenopausal women. Atherosclerosis 2004; 176: 387-92.
18. Sumino H, Ichikawa S, Kasama S, et al. Relationship between carotid atherosclerosis and lumbar spine bone mineral density in postmenopausal women. Hypertens Res 2008; 31: 1191-7.
19. Uyama O, Yoshimoto Y, Yamamoto Y, Kawai A. Bone changes and carotid atherosclerosis in postmenopausal women. Stroke 1997; 28: 1730-2.
20. Sumino H, Ichikawa S, Kasama S, et al. Elevated arterial stiffness in postmenopausal women with osteoporosis. Maturitas 2006; 55: 212-8.
21. Hirose K, Tomiyama H, Okazaki R, et al. Increased pulse wave velocity associated with reduced calcaneal quantitative osteosono index: possible relationship between atherosclerosis and osteopenia. J Clin Endocrinol Metab 2003; 88: 2573-8.
22. Kanis JA, Melton LI 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137-41.
23. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
24. Investigating committee of guidelines for diagnosis and treatment of hyperlipidemias. J Jpn Atheroscler Soc 1997; 25: 1-34.
25. Sumino H, Ichikawa S, Ohyama Y, et al. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women. Am J Cardiol 2005; 96: 148-53.
26. Ohike Y, Kozaki K, Iijima K, et al. Amelioration of vascular endothelial dysfunction in obstructive sleep apnea syndrome by nasal continuous positive airway pressure-possible involvement of nitric oxide and asymmetric NG, NG-dimethylarginine. Circ J 2005; 69: 221-6.
27. Sumino H, Ichikawa S, Kasama S, et al. Effect of transdermal hormone replacement therapy on carotid artery wall thickness and levels of vascular inflammatory markers in postmenopausal women. Hypertens Res 2005; 28: 579-84.
28. Hoshide S, Ishikawa J, Eguchi K, Ojima T, Shimada K, Kario K. Masked nocturnal hypertension and target organ damage in hypertensives with well-controlled self-measured home blood pressure. Hypertens Res 2007; 30: 143-9.
29. Yamashina A, Tomiyama H, Takeda K, et al. Validity, reproducibility, and clinical significance of noninvasive brachialankle pulse wave velocity measurement. Hypertens Res 2002; 25: 359-64.
30. Sumino H, Ichikawa S, Kasama S, et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis 2006; 189: 436-42.
31. Gotoh M, Mizuno K, Ono Y, Takahashi M. High blood pressure, bone-mineral loss and insulin resistance in women. Hypertens Res 2005; 28: 565-70.
32. Simoncini T, Genazzani AR. Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab 2000; 85: 2966-9.
33. Figtree GA, Lu Y, Webb CM, Collins P. Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 1999; 100: 1095-101.
34. Tremollieres FA, Cigagna F, Alquier C, Cauneille C, Pouilles J, Ribot C. Effect of hormone replacement therapy on age-related increase in carotid artery intima-media thickness in postmenopausal women. Atherosclerosis 2000; 153: 81-8.
35. Beldekas JC, Gerstenfeld L, Sonenshein GE, Franzblau C. Cell density and estradiol modulation of procollagen type III in cultured calf smooth muscle cells. J Biol Chem 1982; 257: 12252-6.
36. Fischer GM, Swain ML. Effects of estradiol and progesterone on the increased synthesis of collagen in atherosclerotic rabbit aortas. Atherosclerosis 1985; 54: 177-85.
37. Dubey RK, Gillespie DG, Jackson EK, Keller PJ. 17Beta-estradiol, its metabolites, and progesterone inhibit cardiac fibroblast growth. Hypertension 1998; 31: 522-8.
38. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605-13.
39. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
40. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-12.
41. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 2002; 288: 980-7.
42. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998; 98: 731-3.
43. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial. JAMA 1995; 273: 199-208.
44. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81: 7B-12B.
45. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279: 1445-51.
46. Sbarouni E, Flevari P, Kroupis C, Kyriakides ZS, Koniavitou K, Kremastinos DT. The effects of raloxifene and simvastatin on plasma lipids and endothelium. Cardiovasc Drug Ther 2003; 17: 319-23.
47. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2000; 85: 214-8.
48. Wilkinson IB, Qasem A, McEniery CM, Webb DJ, Avolio AP, Cockcroft JR. Nitric oxide regulates local arterial distensibihty in vivo. Circulation 2002; 105: 213-7.
49. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9. (Review)
50. Kobayashi K, Akishita M, Yu W, Hashimoto M, Ohni M, Toba K. Interrelationship between non-invasive measurements of atherosclerosis: flow-mediated dilation of brachial artery, carotid intima-media thickness and pulse wave velocity. Atherosclerosis 2004; 173: 13-8.